Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067762 | 0.89 | PIK3CD (0.37) | PIK3CDDPP4ACEMAPT | |
| SCHEMBL9252755 | 0.89 | PIK3CD (0.37) | PIK3CDDPP4ACEMAPT | |
| SCHEMBL18067760 | 0.89 | PIK3CD (0.37) | PIK3CDDPP4ACEMAPT | |
| SCHEMBL13559834 | 0.83 | CYP1A2 (0.38) | ACEBACE1GBA1 | |
| SCHEMBL18067766 | 0.81 | ACE (0.43) | PIK3CDDPP4ITGB3ACEMAPT | |
| SCHEMBL18067764 | 0.81 | ACE (0.43) | PIK3CDDPP4ITGB3ACEMAPT | |
| SCHEMBL9252361 | 0.80 | PIK3CD (0.38) | PIK3CDDPP4ACEMAPTBACE1 | |
| SCHEMBL2602295 | 0.78 | DPP4 (0.36) | PIK3CDDPP4ACEMAPT | |
| SCHEMBL18067759 | 0.77 | ACE (0.33) | PIK3CDDPP4ITGB3ITGAVACE | |
| SCHEMBL9259179 | 0.77 | TSHR (0.34) | PIK3CDDPP4ACEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | PIK3CD 1714/4885DPP4 1078/4885ITGB3 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.